Neyroendokrinnye opukholi zheludochnokishechnogo trakta i podzheludochnoy zhelezy kak gastroenterologicheskaya problema


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In the past few years, great interest in the neuroendocrine system, particularly in evaluation of neuroendocrine tumors (NETs) has occurred. This is attributable to the increasing incidence of NETs, and development of modern technologies, allowing a new way to their diagnosis and treatment. NETs is definitely oncological problem. However, the first contact with the patient, and, therefore, timely diagnosis are associated with work of general practitioners and gastroenterologists in outpatient settings, which are often insufficiently aware of this disease. The article is aimed to provide general idea of the NETs, and the modern potentials for their diagnosis and treatment, for physicians and gastroenterologists in particular.

Full Text

Restricted Access

About the authors

A. V Kalinin

Email: neon114@yandex.ru

References

  1. Нейроэндокринные опухоли: руководство для врачей. Перевод с англ. / Под ред. М. Кэплина, Л. Квопса. М., 2010. 224 с.
  2. Yao J, Hassan M, Phan A, et al. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
  3. Булгаков С.А. Даларгин в гастроэнтерологии. М., 2008. 205 с.
  4. Rindi G, Leiter AB, Kopin AS, et al. The «normal» endocrine cell of the gut: changing concepts and new evidences. Ann NY Аса Sci 2004; 1014;1-12.
  5. Modlin IM, Oberg K. A Century all Advances In Neuroendocrine Tumor Biology and Treatment. Hannover, Germany: Felsenstein СССР, 2007.
  6. Fritz A.G. International Classification of Diseases for Oncology: ICD-0. Geneva, Switzerland, World Health Organization, 2000.
  7. Симоненко В.Б., Дулин П.А., Маканин М.А. Карциноиды и нейроэндокринные опухоли. М., 2008. 176 с.
  8. Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. Lancet 1998;352:799-05.
  9. Kulke MH, Mayer RJ. Carcinoid tumours. N Engl J Med 1999;340:858-68.
  10. Zollinger H, Ellison E. Primary peptic ulceration of the jejunum associated with islet cell tumors of pancreas. Ann Surg 1955;142:709-28.
  11. Roy PK, Venzon DJ, Feigenbaum KM, et al. lGastric secretion in Zollinger-Ellisson syndrome. Correlation with clinical expression, tumour extent and role in diagnosis a prospective NIH study of 235 patients a review of 984 cases in the literature. Me: (Baltimore), 2001; 80:189-22.
  12. Jensen RT. Gastrointestina docrine tumours. Gastrinoma. Bailliere; Gastroenterol 1996;10:603-43.
  13. Калинин А.П. Оперативное лечение нейроэндокринных опухолей поджелудочной железы // Рос. журн. гастроэнтерол., гепатол., и колопроктол. 2000. № 5. С. 79-5.
  14. Уголев А.М., Радбиль О.С. Гормоны пищеварительной системы: Физиология, патология, теория функциональных блоков. М., 1995. 283 с.
  15. Kaltsas GA, Besser GM, Grossman AB The diagnosis and medical management of advanced neuroendocrine tumours. Endocrinol Rev 2004;25:458-11.
  16. Deftos LJ. Chromogranin A; its role in endocrine function and as an endocrine and neuroendocrine tumour marker. Endocrin Rev 1991;12:181-87.
  17. Stridsberg M, Oberg K, Engstrom U, Lundquist G. Measurements of chromogranin A, chromogranin В (secretogranin I), chromogranin С (secretogranin II) and pancreostatin in plasma and urina from patients with carcinoid tumours J Endocrinol 1995;144:49-9.
  18. Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008;6:820-27.
  19. Shi W, Johnston CF, Buchanan KD, et al. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM. 1998;91(4):295-301.
  20. Gourtsoyiannis N, Grammatikakis J, Prassopoulos P Role of conventional radiology in the diagnosis and staging of gastrointestinal tract neoplasms. Semin Surg Oncol 2001;20:91-108.
  21. Zimmer T, Scherubl H, Faiss S, et al. Endoscopic ultrasonography of neuroendocrine tumours. Digestion 2000;62(Suppl 1):45-50.
  22. Kalkner KM, Janson ET, Nilsson S et al. Somatostatin receptor scintigraphy patients with carcinoid tumours: comharison between radioligand uptake and tumour markers. Cancer Res 1995;55(23 Suppl):5801s-04s.
  23. Krenning E, Kooij P, Pouwels S, et al. Somatostatin receptor scintigraphy and radionuclide therapy Digest. 1999;57 (suppl. 1):57-1.
  24. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Re 1990; 50:5969-77. зависят от повышения осведомленности врачей общей практики (терапевтов и гастроэнтерологов) о современных возможностях диагностики и лечения НЭО.
  25. Norton JA, Fraker DL, Alexandr HR. et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999;341(9):635-43.
  26. Kelsen DG, Cheng E, Kemeny N, et al. Streptozotocin and Adriamycin in the treatment of APUD tumors (carcinoid islet cell and medullary thyroid) Proc Amer Assoc Cancer Res 1982;23;433-39.
  27. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin and streptozocin in thtreatment of patients with metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;23:4762-71.
  28. Degen L, Beglinger C. The role of octreotide in the treatment of gastroen_teropancreatic endocrine tumor. Digest. 1999;60(Suppl. 2):9-14.
  29. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system Ann Oncol 2004;57:966-73.
  30. Eriksson B, Oberg К. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumours: future outlook. 1999 Ann Oncol 10(Suppl. 2):3-38.
  31. Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001;37:1014-19.
  32. Rinke A, Muller H, Schade-Brittinger C, et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group J Clin Oncol 2009;27:3492-4000.
  33. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177LuDOTAO,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumours. J Clin Oncol 2005;23:2754-62.
  34. Valkerna R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3] octreotide in patients with advanced gastro-enteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147-56.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies